San Diego, CA / ACCESSWIRE / November 25, 2014 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC") and consumer products for men's and women's health and vitality announced today a positive analysis and outcome of a 246 use survey study in the United Kingdom for Zestra(R) in women, conducted by Semprae Laboratories prior to its acquisition by Innovus Pharma, but never reported. In this use survey study, 246 women, including a large number of nurse practitioners between the ages of 30-60 years old, used Zestra(R) over a period of two weeks. Users were asked to answer a modified diary of the FSFI score.
Results reported Include:
1. Achievement of 77% increase in intense sensation and arousal with the use of Zestra(R)
2. 66% reported an ease in orgasm
3. 56% reported a more intense orgasm
4. 40% of women used Zestra(R) once to twice a week
5. No adverse events were reported from the users
6. User satisfaction increased from 48.5% to approximately 74.7%
7. Partner satisfaction increased from approximately 59.2 % to over approximately 77.9%
"The results from this study statistically mirror the results from the two published placebo double-blind trials run in the US population of users of Zestra(R) previously reported and show that Zestra(R) works across multiple ethnic populations" said Dr. Bassam Damaj, President & CEO of Innovus Pharmaceuticals. "Additional use survey studies are currently ongoing in Denmark and Germany."
"We believe the results obtained with Zestra(R) in the British population are a testimony to the clinical efficacy of Zestra(R), and should be a valuable addition to the regulatory dossier of Zestra(R) with the European Health Authorities, and an asset for the on-going out-licensing commercial efforts that Company is undertaking," continued Dr. Damaj.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC consumer products for men’s and women's health and vitality. The Company generates revenues from its lead products Zestra (R) for female arousal, and EjectDelay(TM) for premature ejaculation, and has a total of five marketed products in this space, including Sensum+(TM) (for sales outside the U.S. only), Zestra Glide(R) and Vesele(R) for increasing blood flow.
For more information, go to www.innovuspharma.com.
Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products such as Zestra(R), to successfully commercialize such products in the United Kingdom, Europe and in other countries and regions, and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
###
Innovus Pharma
Contact:
Kevin Holmes
Chesapeake Group
[email protected]
T: 410-825-3930
SOURCE: Innovus Pharmaceuticals, Inc.